Dublin, June 15, 2021 (GLOBE NEWSWIRE) -- The "Global Nanomedicines Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Nanotechnology involves the miniaturization of larger structures and chemicals at a nanometric scale for drug administration. The global nanomedicines market is projected to grow at a modest CAGR of 11.1% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the various innovations in nanotechnology for medicines along with the rise in the prevalence of various diseases such as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others. Developments in nanorobotics along with government support are further expected to propel the growth of the market over the forecast period.

The global nanomedicines market is segmented on the basis of indication type and application. Based on the indication type, the market is segmented as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others. The other segment includes urological disease and ophthalmic diseases. The cardiovascular diseases segment is likely to hold a substantial share in the market over the forecast period. Based on the applications, the market is segmented as drug delivery, active implants, vaccines, diagnostic imaging, biomaterials, regenerative medicines, and other applications. The other segment includes tissue regeneration. The drug delivery segment is likely to hold a substantial share in the market over the forecast period.

Based on the demographic viewpoint, the market is segmented as North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is projected to hold a significant market share over the forecast period owing to various R&D activities conducted by the key players. Further, 3M Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca Plc., Celgene Corp., Pfizer Inc., Sanofi SA, and Smith & Nephew Plc among others are some of the prominent players functioning in the global Nanomedicine market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.

Market Segmentation:

1. Global Nanomedicine Market Research and Analysis by Indication Type2. Global Nanomedicine Market Research and Analysis by Applications

The Report covers:

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights2.1. Scope of the Report2.2. Analyst Insight & Current Market Trends2.2.1. Key Findings2.2.2. Recommendations2.2.3. Conclusion

3. Competitive Landscape3.1. Competitive Dashboard3.2. Key Strategy Analysis3.3. Key Company Analysis3.3.1. 3M Co.3.3.1.1. Overview3.3.1.2. Financial Analysis3.3.1.3. SWOT Analysis3.3.1.4. Recent Developments3.3.2. Johnson & Johnson Services Inc.3.3.2.1. Overview3.3.2.2. Financial Analysis3.3.2.3. SWOT Analysis3.3.2.4. Recent Developments3.3.3. Merck & Co. Inc.3.3.3.1. Overview3.3.3.2. Financial Analysis3.3.3.3. SWOT Analysis3.3.3.4. Recent Developments3.3.4. Thermo Fisher Scientific Inc.3.3.4.1. Overview3.3.4.2. Financial Analysis3.3.4.3. SWOT Analysis3.3.4.4. Recent Developments3.3.5. Eli Lily & Co.3.3.5.1. Overview3.3.5.2. Financial Analysis3.3.5.3. SWOT Analysis3.3.5.4. Recent Developments

4. Market Determinants4.1. Motivators4.2. Restraints4.3. Opportunities

5. Market Segmentation5.1. Global Nanomedicine Market by Indication Type5.1.1. Cardiovascular Diseases5.1.2. Neurological Diseases5.1.3. Infectious Diseases5.1.4. Oncological Diseases5.1.5. Orthopedic Diseases5.1.6. Other Diseases (Urological Disease, Ophthalmic Diseases)5.2. Global Nanomedicine Market by Application5.2.1. Drug Delivery5.2.2. Active Implants5.2.3. Vaccines5.2.4. Diagnostic Imaging5.2.5. Biomaterials5.2.6. Regenerative Medicines5.2.7. Other Applications (Tissue Regeneration)

6. Regional Analysis6.1. North America6.1.1. United States6.1.2. Canada6.2. Europe6.2.1. UK6.2.2. Germany6.2.3. Italy6.2.4. Spain6.2.5. France6.2.6. Rest of Europe6.3. Asia-Pacific6.3.1. China6.3.2. India6.3.3. Japan6.3.4. ASEAN6.3.5. South Korea6.3.6. Rest of Asia-Pacific6.4. Rest of the World

7. Company Profiles7.1. Affymetrix Inc.7.2. AstraZeneca Plc.7.3. Bristol-Myers Squibb Co.7.4. Celgene Corp.7.5. CytImmune Sciences Inc.7.6. Ferro Corp.7.7. GE Global Research7.8. Gilead Sciences Inc.7.9. Luminex Corp.7.10. Nanobiotix SA7.11. PerkinElmer Inc.7.12. Pfizer Inc.7.13. Sanofi SA7.14. Shimadzu Co. Ltd7.15. Smith & Nephew Plc7.16. St. Jude Medical Inc.7.17. Starpharma Holdings Ltd.7.18. Stryker Corp.7.19. Taiwan Liposome Co. Ltd.7.20. UCB SA

For more information about this report visit https://www.researchandmarkets.com/r/vnosdc

More:

Insights on the Nanomedicines Global Market to 2026 - - GlobeNewswire